Trading / Browse Companies / PMV Pharma Stock

PMV Pharma Stock

pmvpharma.comHealthcareFounded: 2013Funding to Date: $170.8MM

PMV is a biotechnology company dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Buy or sell PMV Pharma stockLearn more about a potential PMV Pharma IPO
Register for Details

For more details on financing and valuation for PMV Pharma, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for PMV Pharma.

Register Today

Team

Management Team

David Mack Ph.D
Board Member, Co-Founder, Chief Executive Officer & President
Arnold Levine Ph.D
Board Member, Co-Founder & Member of Scientific Advisory Board
Thomas Shenk Ph.D
Co-Founder & Member of the Scientific Advisory Board
Binh Vu Ph.D
Vice President of Chemistry
Winston KUng
Chief Operating Officer & Chief Financial Officer
Thomas Davis Ph.D
Vice President of Biology

Board Members

Arnold Levine Ph.D
Peter Thompson MD
OrbiMed
Arnold Oronsky Ph.D
InterWest Partners
Steven Winick JD
Topspin Venture
David Mack Ph.D
Douglas Fisher MD
InterWest Healthcare Partners
Thilo Schroeder Ph.D
Nextech Invest

Other companies like PMV Pharma in the Healthcare sector

Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.6B
NowRx
Sector
Healthcare
Last Round Est. Valuation
$334.19MM
Nutrafol
Sector
Healthcare
Last Round Est. Valuation
$150MM
Biosplice Therapeutics
Sector
Healthcare
 
 
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Cytonics
Sector
Healthcare
 
 
Levels
Sector
Healthcare
Last Round Est. Valuation
$296.3MM
Cerebral
Sector
Healthcare
Last Round Est. Valuation
$4.8B

News

PR Web 11/13/2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
PR Newswire 03/19/2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
/PRNewswire/ -- PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today...

Trending Companies

Frequently Asked Questions